Detection Systems For Human tissue｜Immunohistochemistry

DETECTION SYSTEMS
For Human tissue

TOP > Immunohistochemistry > Detection Systems > Detection Systems For Human tissue

2 step HRP polymer

N-Histofine® High Stain™ HRP(MULTI)

N-Histofine® High Stain™ HRP(MULTI)is the Two-Step Polymer Detection System forIHC staining providing more amplified staining intensity compared with conventional One-step polymer detection system. This system is applicable to both of Mouse and Rabbit primary antibodies and is for formalin-fixed, paraffin-embedded tissue sections. It is the labeled polymer prepared by combining amino acid polymers with multiple molecules of peroxidase(PO) and secondary antibody which is reduces to Fab’ fragment. To eliminate background staining, solid-phase adsorption of secondary antibody is conducted with human serum.

You can check it by scrolling→

Product Name	Slides	Volume	Code	For use with	Instruction
N-Histofine® High Stain™ HRP(MULTI)	170	1x17ml each	414481F	Mouse and rabbit primary antibodies
N-Histofine® High Stain™ HRP(MULTI)	1000	6x17ml each	414483F	Mouse and rabbit primary antibodies

1 step HRP polymer

N-Histofine® Simple Stain™ Max PO

N-Histofine® Simple Stain™ MAX PO is a detection reagent designed specifically to allow immunohistochemical staining on formalin-fixed paraffin-embedded human tissue sections. It is the labeled polymer prepared by combining amino acid polymers with multiple molecules of peroxidase (PO) and secondary antibody which is reduced to Fab’ fragment. To eliminate background staining, solid-phase adsorption of secondary antibody is carried out with human serum.

You can check it by scrolling→

Product Name	Slides	Volume	Code	For use with
N-Histofine® Simple Stain™ MAX PO(MULTI)	170	1x17ml each	414151F	Mouse and rabbit primary antibodies
	500	3x17ml each	414152F
	1500	9x17ml each	414154F
N-Histofine® Simple Stain™ MAX PO(M)	170	1x17ml each	414131F	Mouse primary antibodies
	500	3x17ml each	414132F
	1500	9x17ml each	414134F
N-Histofine® Simple Stain™ MAX PO(R)	170	1x17ml each	414141F	Rabbit primary antibodies
	500	3x17ml each	414142F
	1500	9x17ml each	414144F
N-Histofine® Simple Stain™ MAX PO(G)	170	1x17ml each	414161F	Goat primary antibodies
N-Histofine® Simple Stain™ MAX PO(G)	500	3x17ml each	414162F	Goat primary antibodies

Product Name	Slides	Volume	Code	For use with
N-Histofine® Simple Stain™ MAX PO(MULTI)	170	1x17ml each	414151F	Mouse and rabbit primary antibodies
	500	3x17ml each	414152F
	1500	9x17ml each	414154F
N-Histofine® Simple Stain™ MAX PO(M)	170	1x17ml each	414131F	Mouse primary antibodies
	500	3x17ml each	414132F
	1500	9x17ml each	414134F
N-Histofine® Simple Stain™ MAX PO(R)	170	1x17ml each	414141F	Rabbit primary antibodies
	500	3x17ml each	414142F
	1500	9x17ml each	414144F

1 step AP polymer

N-Histofine® Simple Stain™ AP

N-Histofine® Simple Stain™ AP is a detection reagent designed specifically to allow immunohistochemical staining on formalin-fixed paraffin-embedded human tissue sections. It is the labeled polymer prepared by combining amino acid polymer with alkaline phosphatase (AP) and secondary antibody which is reduced to Fab’ fragment. To eliminate background staining, solid-phase adsorption of secondary antibody is carried out with human serum.

You can check it by scrolling→

Product Name	Slides	Volume	Code	For use with
N-Histofine® Simple Stain™ AP(MULTI)	170	1x17ml each	414261F	Mouse and rabbit primary antibodies
N-Histofine® Simple Stain™ AP(MULTI)	500	3x17ml each	414262F	Mouse and rabbit primary antibodies
N-Histofine® Simple Stain™ AP(M)	170	1x17ml each	414241F	Mouse primary antibodies
N-Histofine® Simple Stain™ AP(M)	500	3x17ml each	414242F	Mouse primary antibodies
N-Histofine® Simple Stain™ AP(R)	170	1x17ml each	414251F	Rabbit primary antibodies
N-Histofine® Simple Stain™ AP(R)	500	3x17ml each	414252F	Rabbit primary antibodies

Reference

■　Human Tissue Sections

Simple Stain™ MAX PO (MULTI)

(1) Mokrỳ, et al. Versatility of immunohistochemical reactions: comprehensive survey of detection systems. Acta medica 1996 Apr 39:129-40
(2) Yamada K, et al. In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms. J Mater
Sci Mater Med. 2021 May 17;32(6):58. .
(3) Rahman A, et al. Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer. Int J Mol Sci. 2021 Apr 6;22(7):3774.
(4) Tanaka Y, et al. A Novel Therapeutic Target for Melanoma. Int J Mol Sci. 2021 Jan 19;22(2):976.
(5) Matsumoto NM, et al. Gene Expression Profile of Isolated Dermal Vascular Endothelial Cells in Keloids. Front Cell Dev Biol. 2020 Jul 29;8:658.
(6) Oriuchi N, et al. Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4
monoclonal antibody. Sci Rep. 2020 Apr 22;10(1):6810.
(7) Ichinokawa K, et al. Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small
-cell lung cancer. Oncol Lett. 2019 Jul;18(1):117-126.
(8) Yazawa T, et al. Prognostic significance of β2-adrenergic receptor expression in non-small cell lung cancer. Am J Transl Res. 2016 Nov
15;8(11):5059-5070.
(9) Uchida T, et al. CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS. Sci Rep. 2016 Jan
11;6:19118.
(10) Xing T, et al. Immunity of fungal infections alleviated graft reject in liver transplantation compared with non-fungus recipients. Int J Clin
Exp Pathol. 2015 Mar 1;8(3):2603-14.
(11) Kaira K, et al. Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic
cancer. Am J Transl Res. 2015 Feb 15;7(2):356-63.
(12) Toyoda M, et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
Br J Cancer. 2014 May 13;110(10):2506-13.
(13) Bychkov A, et al. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry. Thyroid. 2013 Jul;23(7):817-28.

Simple Stain™ MAX PO (M)

(1) Mokrỳ, et al. Versatility of immunohistochemical reactions: comprehensive survey of detection systems. Acta medica 1996 Apr 39:129-40
(2) Kaji S, et al. BCAS1-positive immature oligodendrocytes are affected by the α-synuclein-induced pathology of multiple system atrophy.
Acta Neuropathol Commun. 2020 Jul 29;8(1):120.
(3) Kobayashi S, et al. Image analysis of the nuclear characteristics of emerin protein and the correlation with nuclear grooves and
intranuclear cytoplasmic inclusions in lung adenocarcinoma. Oncol Rep. 2019 Jan;41(1):133-142.
(4) Kudo I, et al. Particular gene upregulation and p53 heterogeneous expression in TP53-mutated maxillary carcinoma. Oncol Lett. 2017
Oct;14(4):4633-4640.
(5) Shimura T, et al. MIB-1 labeling index, Ki-67, is an indicator of invasive intraductal papillary mucinous neoplasm. Mol Clin Oncol. 2016
Aug;5(2):317-322.
(6) Ishiwata T, et al. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J
Pathol. 2012 May;180(5):1928-41.
(7) Tsuji S, et al. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br J Cancer. 2010 Aug
10;103(4):517-23.
(8) Tanioka Y, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial
oesophageal cancer. Br J Cancer. 2003 Dec 1;89(11):2116-21.

Simple Stain™ MAX PO (R)

(1) Mokrỳ, et al. Versatility of immunohistochemical reactions: comprehensive survey of detection systems. Acta medica 1996 Apr 39:129-40.
(2) Sudo S, et al. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell
carcinoma. Cancer Sci. 2020 Apr;111(4):1113-1123.
(3) Kudo I, et al. Particular gene upregulation and p53 heterogeneous expression in TP53-mutated maxillary carcinoma. Oncol Lett. 2017
Oct;14(4):4633-4640.
(4) Ishiwata T, et al. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J
Pathol. 2012 May;180(5):1928-41.
(5) Tsuji S, et al. Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion. Br J Cancer. 2010 Aug
10;103(4):517-23.
(6) Yokota N, et al. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer. 2009 Dec
15;101(12):2023-9.